Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Burg, Bernhard Sixt, Nicolas Pasqual

Premium

Insight Genetics, based in Nashville, Tenn., said that David Burg has joined the company as associate director of business development. Burg will lead sales and marketing for the company's Insight Molecular Labs. Prior to joining Insight, Burg was regional sales director for Response Genetics. He has also been a senior executive oncology account manager with GlaxoSmithKline.


ImmunID announced that it has appointed Bernhard Sixt to be company president and CEO, and Nicolas Pasqual, the firm's co-founder and former CEO, to be its chief scientific officer. Sixt co-founded Agendia and served as its CEO from 2003 to 2011, and he has over 25 years of experience in the development and commercialization of diagnostics, pharmaceuticals, and lab services at companies like Amersham and Nycomed.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.